Ustun Celalettin, Courville Elizabeth L, DeFor Todd, Dolan Michelle, Randall Nicole, Yohe Sophia, Bejanyan Nelli, Warlick Erica, Brunstein Claudio, Weisdorf Daniel J, Linden Michael A
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Biol Blood Marrow Transplant. 2016 Apr;22(4):669-675. doi: 10.1016/j.bbmt.2015.10.024. Epub 2015 Nov 10.
Stringent complete remission (CR) in acute myeloid leukemia (AML) requires the absence of both morphologic and flow cytometric evidence of disease. We have previously shown that persistent AML detected by flow cytometry (FC+) before reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT) was associated with significantly increased relapse, shorter disease-free survival (DFS), and poorer overall survival (OS), independent of morphologic blast count. We evaluated the effect of FC status on outcomes of alloHCT for AML after either myeloablative conditioning (MAC) or RIC regimens in 203 patients (MAC, n = 80, and RIC, n = 123) with no morphologic evidence of persistent AML pretransplant on marrow biopsy. The allografts included 130 umbilical cord blood (UCB) and 73 sibling donors. We performed central review of pretransplant standard sensitivity FC to identify detectable FC+. Twenty-five patients were FC+, including 15 (18.7%) receiving MAC and 10 (8.1%) RIC alloHCT. Among RIC patients FC+ was associated with significantly inferior relapse, DFS, and OS (multiple regression HR, 3.8; 95% CI, 1.7 to 8.7; P < .01 for relapse; HR, 2.9; 95% CI, 1.4 to 5.9; P < .01 for DFS; and HR, 3.4; 95% CI, 1.7 to 7; P < .01 for OS). In contrast, FC+ status was not associated with relapse or decreased OS after MAC. These data suggest that MAC, but not RIC, overcomes the negative effect of pretransplant FC+ after sibling or UCB alloHCT. Therefore, a deeper pretransplant leukemia-free state is preferred for those treated with RIC.
急性髓系白血病(AML)的严格完全缓解(CR)要求无疾病的形态学和流式细胞术证据。我们之前已经表明,在减低强度预处理(RIC)异基因造血细胞移植(alloHCT)前通过流式细胞术检测到的持续性AML(FC+)与复发显著增加、无病生存期(DFS)缩短和总生存期(OS)较差相关,与形态学原始细胞计数无关。我们评估了FC状态对203例在骨髓活检时无持续性AML形态学证据的患者在清髓性预处理(MAC)或RIC方案后进行alloHCT治疗AML结局的影响。移植物包括130份脐带血(UCB)和73例同胞供者。我们对移植前标准敏感性FC进行了中心审查,以识别可检测到的FC+。25例患者为FC+,其中15例(18.7%)接受MAC alloHCT,10例(8.1%)接受RIC alloHCT。在RIC患者中,FC+与显著较差的复发、DFS和OS相关(多元回归风险比,3.8;95%置信区间,1.7至8.7;复发P<0.01;风险比,2.9;95%置信区间,1.4至5.9;DFS P<0.01;风险比,3.4;95%置信区间,1.7至7;OS P<0.01)。相比之下,FC+状态与MAC后的复发或OS降低无关。这些数据表明,MAC而非RIC克服了同胞或UCB alloHCT后移植前FC+的负面影响。因此,对于接受RIC治疗的患者,更倾向于移植前达到更深的无白血病状态。